Reid Hoffman leads $12M Series A in Sanmai Technologies—a stealth startup building a sub‑$500, AI‑powered ultrasound headset to non‑invasively treat mental health and boost cognition from the comfort of home . Joining the board, Hoffman backs Sanmai’s use of low‑intensity focused ultrasound to precisely target brain regions—dabbling where traditional meds falter. The real kicker? An embedded AI companion that adapts treatment to the user and navigates technical hurdles like skull distortion . CEO Jay Sanguinetti, with over a decade of research behind him, is already running clinical trials—starting with anxiety—in Sunnyvale . As ultra‑large brain‑tech like Neuralink push surgical extremes, Sanmai bets on a safer, scalable consumer path backed by FDA‑engaged clinical data. A paradigm‑shifting step in digital therapeutics and mental wellness.

Bloomberg